26 C
Vientiane
Tuesday, October 7, 2025
spot_img
Home Blog Page 568

ZKH Group Limited to Announce Second Quarter 2025 Financial Results on Friday, August 22, 2025

SHANGHAI, Aug. 8, 2025 /PRNewswire/ — ZKH Group Limited (“ZKH” or the “Company”) (NYSE: ZKH), a leading maintenance, repair and operations (“MRO”) procurement service platform in China, today announced that it will release its unaudited financial results for the second quarter of 2025, on Friday, August 22, 2025, before the open of the U.S. markets.

The Company’s management will hold an earnings conference call on Friday, August 22, 2025 at 8:00 A.M. U.S. Eastern Time (8:00 P.M. Beijing/Hong Kong Time) to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States (toll free):

+1-888-317-6003

International:

+1-412-317-6061

Mainland China (toll free):

400-120-6115

Hong Kong (toll free):

800-963-976

Hong Kong:

+852-5808-1995

Access Code:

6971877

A replay of the conference call will be accessible by phone one hour after the conclusion of the live call at the following numbers, until August 29, 2025:

United States:

+1-877-344-7529

International:

+1-412-317-0088

Replay Access Code:       

5489224

A live and archived webcast of the conference call will also be available on the Company’s investor relations website at https://ir.zkh.com.

About ZKH Group Limited

ZKH Group Limited (NYSE: ZKH) is a leading MRO procurement service platform in China, underpinned by robust supply chain capabilities and dedicated to serving customers globally through a product-led, agentic AI-driven approach. Through its primary online platforms, the ZKH platform, the GBB platform and the Northsky platform, along with innovative technology and extensive industry expertise, the Company provides bespoke MRO procurement solutions to a diverse and loyal customer base. These solutions encompass hyper-personalized product curation from a comprehensive selection of quality products at competitive prices. Additionally, the Company ensures timely and reliable product delivery through professional fulfillment services. By focusing on reducing procurement costs and addressing management efficiency challenges, ZKH is transforming the opaque MRO procurement process and empowering all stakeholders across the value chain.

For more information, please visit https://ir.zkh.com.

For investor and media inquiries, please contact:

In China:

ZKH Group Limited
IR Department
E-mail: IR@zkh.com

Piacente Financial Communications
Hui Fan
Tel: +86-10-6508-0677
E-mail: zkh@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: zkh@thepiacentegroup.com

Truecaller, crosses 100M monthly active users in Middle East and Africa

STOCKHOLM, Aug. 8, 2025 /PRNewswire/ — Truecaller, the leading global platform for verifying contacts and blocking unwanted communications, reached a significant milestone in August as the number of monthly active users (Android and iOS) crossed 100 million in the MEA-region, representing a 19% growth y-o-y.

“With the Middle East and Africa experiencing significant growth in smartphone adoption and mobile data adoption, we’re really happy that we’re able to solve communication problems for individuals and businesses in that region. MEA, like India and many other markets, are mobile first markets with your mobile number being the primary identifier, and Truecaller has always grown organically in such markets. We’re continuing to strengthen our organization and our partnerships in the region, because we believe that the MEA is poised for significant growth for many years ahead,” said Rishit Jhunjhunwala, CEO.

Some of the largest markets in MEA for Truecaller are Egypt, Nigeria, South Africa, Kenya, Algeria, Ghana, and Jordan where Truecaller is used on 20-45% of connected smartphones in those markets.

For more information, please contact:
Andreas Frid, Head of IR & Communication
+46 705 29 08 00
andreas.frid@truecaller.com

About Truecaller

Truecaller (TRUE B) is the leading global platform for verifying contacts and blocking unwanted communication. We enable safe and relevant conversations between people and make it efficient for businesses to connect with consumers. Fraud and unwanted communication are endemic to digital economies. especially in emerging markets. We are on a mission to build trust in communication. Truecaller is an essential part of everyday communication for more than 450 million active users. Truecaller is listed on Nasdaq Stockholm since 8 October 2021. For more information please visit corporate.truecaller.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/truecaller-ab/r/truecaller–crosses-100m-monthly-active-users-in-middle-east-and-africa,c4215814

The following files are available for download:

https://mb.cision.com/Main/20429/4215814/3603228.pdf

Press release 100 m users in MEA 250808

 

RemeGen’s Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

YANTAI, China, Aug. 8, 2025 /PRNewswire/ — On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple advanced malignant solid tumors in the US.

RC148 is a PD-1 and VEGF-targeting bispecific antibody, an innovative molecule developed by RemeGen using its bispecific antibody technology platform. Currently, the clinical trials of RC148 as monotherapy and combination therapy for the treatment of advanced solid tumor are proceeding in China.

The clearance of IND application by the FDA is a significant milestone for RC148 which should expedite its global development process.

AXA Signs Cooperation Agreement with Hainan Boao Lecheng Administration

Jointly explore innovative medical insurance services to provide customers with diverse and high-quality healthcare options

HONG KONG, Aug. 8, 2025 /PRNewswire/ — AXA China Region Insurance Company (Bermuda) Limited (“AXA”) formally signed an official cooperation agreement with Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (“Lecheng Administration”). The partnership aims jointly explore more innovative medical insurance models and leverage the top-tier medical resources of Hainan Boao Lecheng to provide customers with more high-quality cross-border medical options.

The Hainan Boao Lecheng International Medical Tourism Pilot Zone (“the Pilot Zone”) was approved by the State Council[1] in 2013 as the only medical special zone in China, enjoying preferential policies covering licensed medical services, operations, research, and international exchanges. Since approval, the Pilot Zone has attracted leading medical institutions and specialist teams, introducing advanced international treatment protocols, innovative pharmaceuticals, and medical devices into China for trial use – including therapies for rare diseases and cutting-edge cancer treatments. Meanwhile, AXA has partnered with China Biotech Services Holdings Limited to explore Boron Neutron Capture Therapy (“BNCT”), a pioneering initiative now being established within the Pilot Zone.

Janet Lee, Chief Life and Health Insurance Officer, AXA Hong Kong and Macau, said, “We are honoured to have signed a cooperation agreement with the Lecheng Administration. As a pioneer in China’s medical opening-up, Hainan Boao Lecheng benefits from unique policy advantages and strong support from global healthcare resources. This collaboration will enable AXA to explore innovative healthcare solutions and integrate them into our insurance offerings, providing customers with broader access to advanced treatment options. We look forward to deepening our partnership with Lecheng and other stakeholders to develop innovative medical models, enabling more customers to benefit from Lecheng’s licensed medicines, medical devices, and cutting-edge technologies.”

AXA China Region Insurance Company (Bermuda) Limited, AXA International Reinsurance (Shanghai) Company  Limited, together with China Biotech Services Holdings Limited, Qianhai Reinsurance Company Limited, and Gallagher  Insurance Brokers (Hong Kong) Limited, signed a memorandum of understanding to jointly explore and develop Boron  Neutron Capture Therapy and related services, providing customers with diversified treatment options.
AXA China Region Insurance Company (Bermuda) Limited, AXA International Reinsurance (Shanghai) Company Limited, together with China Biotech Services Holdings Limited, Qianhai Reinsurance Company Limited, and Gallagher Insurance Brokers (Hong Kong) Limited, signed a memorandum of understanding to jointly explore and develop Boron Neutron Capture Therapy and related services, providing customers with diversified treatment options.

About AXA Hong Kong and Macau

AXA Hong Kong and Macau is a member of the AXA Group, a leading global insurer with presence in 50 markets and serving 95 million customers worldwide. Our purpose is to act for human progress by protecting what matters.

As one of the most diversified insurers in Hong Kong, we offer integrated solutions across Life, Health and General Insurance. We are the largest General Insurance provider and a major Health and Employee Benefits provider. Our aim is to not only be the insurer to provide comprehensive protection to our customers, but also a holistic partner to the individuals, businesses and community we serve. At the core of our service commitment is continuous product & service innovation and customer experience enrichment, which is achieved through actively listening to our customers’ needs and leveraging and investing in technology and digital transformation.

We embrace our responsibility to be a driving force against climate change and a force for good to create shared value for our community. We are proud to be the first to address the importance of mental health through different products and services and thought leading iconic research. Our overall Sustainability Strategy, with emphasis on climate strategy and biodiversity commitment, is developed based on TCFD recommendations. We are committed to integrating environmental, social and governance factors across our business and strive to contribute to a sustainable future through 3 distinct roles – as an investor, an insurer and an exemplary company.

THIS PRESS RELEASE IS AVAILABLE ON AXA’S WEBSITE: AXA.COM.HK

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 – “Risk factors and risk management” of AXA’s Universal Registration Document for the year ended December 31, 2019, for a description of certain important factors, risks and uncertainties that may affect AXA’s business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as part of applicable regulatory or legal obligations.

 

Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests

Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring.

HONG KONG, Aug. 8, 2025 /PRNewswire/ — Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, today announced an exclusive collaboration with Pacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong.

Product Photo
Product Photo

Under this partnership, Codex Genetics will offer access to Cxbladder’s full range of clinically validated tests—including Cxbladder Detect, Cxbladder Monitor, and Cxbladder Triage—designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to deliver actionable insights earlier in the patient care pathway.

Importantly, following a February 2025 update, Cxbladder Triage is included in the Microhematuria Guideline[1] issued by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The amended Guideline incorporates language supporting the use of urine-based biomarkers to reduce reliance on cystoscopy and Cxbladder Triage is mentioned specifically, supported with “Grade A” evidence from a randomized controlled trial – the STRATA study[2].

“Our collaboration with Cxbladder reflects Codex’s continued commitment as a leading diagnostics company in Hong Kong to advance precision medicine across Asia,” said Dr. Aldrin Yim, co-founder of Codex Genetics. “Bladder cancer is one of the most expensive cancers to manage due to its high recurrence rate and need for lifelong monitoring. By offering a reliable non-invasive alternative that can reduce the need for cystoscopy, we aim to enhance clinical workflows, allowing clinicians to prioritize time and resources on those who need it the most. This improves the quality of care for patients in both public and private healthcare systems.”

“We are excited to partner with Codex Genetics to expand access to Cxbladder in Hong Kong,” said Dr. Peter Meintjes, CEO of Pacific Edge. “Codex’s regional leadership in precision diagnostics makes them an ideal partner to deliver Cxbladder’s value to clinicians and patients seeking reliable and less burdensome approaches to bladder cancer testing.”

Bladder cancer is the ninth most common cancer worldwide, with high recurrence contributing to its significant clinical and economic burden. Cxbladder has been used in over 100,000 patients globally and is supported by more than 25 peer-reviewed clinical studies demonstrating high sensitivity and negative predictive value. Its adoption can reduce the need for unnecessary invasive procedures and optimize clinical decision-making.

Clinicians in Hong Kong interested in Cxbladder testing may contact Codex Genetics via www.codexgenetics.com for onboarding and access information.

[1] Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490.

[2] Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.

 

Contact:
Whatsapp: (+852) 9837 1345
Phone: (+852) 3008 2560
Email: support@codexgenetics.com 

HK-listed IVD Medical Invests HK$149M in Ethereum through HashKey Exchange

HONG KONG, Aug. 8, 2025 /PRNewswire/ — HashKey Exchange, Hong Kong’s largest * licensed virtual asset trading platform, has entered into a strategic partnership with IVD Medical Holdings Limited, a publicly listed company on the Hong Kong Stock Exchange. The two parties will collaborate to advance enterprise-level digital asset adoption and explore new models for integrating blockchain with industrial capital.


IVD Medical has made a pioneering move with a HK$149 million Ethereum purchase via HashKey Exchange. With access to trading and liquidity services provided by HashKey Exchange, IVD Medical is poised to become a pioneering “Ethereum treasury” among HK-listed companies. This partnership also marks a further step by HashKey Exchange in advancing the compliant adoption and integration of digital assets within traditional industries and Hong Kong’s capital markets.

Key areas of collaboration include:

  • Block Trade Execution: Access to highly efficient and cost-effective ETH execution via HashKey OTC.
  • Liquidity Provision: Support for large-scale transactions through HashKey Exchange’s global liquidity network.
  • Asset Optimization Initiatives: Explore yield-enhancement opportunities, including ETH staking, restaking, and DeFi yield strategies, in collaboration with HashKey Cloud, the Web3 infrastructure arm of HashKey Group.

Randall Chan, MD of HashKey Exchange, commented:
“IVD Medical’s forward-looking move into digital assets demonstrates how traditional industries are embracing innovation to drive growth. HashKey Exchange remains committed to the highest standards of compliance, security, and transparency, and we look forward to supporting IVD Medical in building its Ethereum treasury and exploring the tokenization of healthcare assets. Together, we aim to bridge the digital and real economies and contribute to Hong Kong’s position as a global hub for financial innovation.”

Gary Deng, Chief Strategy Officer of IVD Medical, added:
“We are delighted to partner with HashKey Exchange. The digital economy is the engine of future growth, and traditional industries must actively integrate to stay ahead in this new wave of technological transformation. Through this collaboration, IVD Medical aims to establish itself as a leading Ethereum Treasury player, strengthen its resilience against market volatility, and deliver long-term value to shareholders.”

About HashKey Exchange

HashKey Exchange is setting a new benchmark for virtual asset trading platforms with its commitment to regulatory compliance, fund security, and platform safety. Operated by Hash Blockchain Limited, it is one of the first licensed retail virtual asset exchanges in Hong Kong. The platform is fully regulated by the Securities and Futures Commission (SFC), holding Type 1 (Dealing in Securities) and Type 7 (Providing Automated Trading Services) licenses under the Securities and Futures Ordinance, as well as a virtual asset trading platform license under the Anti-Money Laundering and Counter-Terrorist Financing Ordinance.

As the flagship business of HashKey Group, HashKey Exchange offers a one-stop trading platform for both professional and retail investors. The exchange is certified under ISO 27001 (Information Security Management) and ISO 27701 (Privacy Information Management), ensuring the highest standards of operational and data security.

In strict compliance with applicable regulations, HashKey Exchange does not provide services to users in Mainland China, the United States, and certain other jurisdictions.

* As of August 8, 2025, HashKey Exchange ranks 17th on CoinGecko, making it the highest-ranked licensed virtual asset exchange in Hong Kong.

WuXi XDC Included in MSCI China All Share Index

SHANGHAI, Aug. 8, 2025 /PRNewswire/ — WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the MSCI China All Share Index, which underscores global capital markets’ recognition of the company’s sustained growth value and leadership in the bioconjugate CRDMO sector. The inclusion will take place as of the close of August 26, 2025.

The MSCI China All Share Index is a free-float-adjusted market-capitalization-weighted index designed to measure the equity-market performance of Chinese companies accessible to international investors, representing the opportunity set of China share classes. It captures large and mid-cap representation across various share classes, including A-shares, H-shares, B-shares, and foreign listings.

WuXi XDC’s inclusion will enhance its visibility and liquidity in international capital markets, offering global investors a compelling opportunity to participate in China’s growing biopharmaceutical innovation. Looking ahead, we will continue advancing bioconjugate technological innovation and development in collaboration with global partners, ultimately expanding treatment options for patients worldwide, as a leading global CRDMO in bioconjugates.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor: wuxixdc.ir@wuxibiologics.com
Media: wuxixdc_pr@wuxibiologics.com
BD: wuxixdc_info@wuxibiologics.com

Foreign Media Delegation Explores China’s Smart Rail Development

BEIJING, Aug. 8, 2025 /PRNewswire/ — This is a news report from China Story: 23 media representatives from 12 Asian and African countries visited the Xitie Education and Training Base in Xi’an, China, gaining firsthand insights into the modern training model of China’s railway enterprises and the country’s advancements in intelligent railway development.

 

Foreign Media Delegation Explores China’s Smart Rail Development

During an interview, Amir Faisol, a journalist at IDN Times, spoke highly of the jointly built Jakarta–Bandung High-Speed Railway, describing it as a highly impactful project that has been warmly received by the public.

Nausheen Yusuf, Senior Journalist at Geo TV, was impressed by the train’s high operating speed and took the opportunity to try out an immersive EMU cab simulator at the event.

Mirzaolim Mirzokhid Ugli Rustambekov from MY5 TV Channel highlighted “innovation” as the key word that captured his experience in Xi’an, China.

By the end of 2024, China’s high-speed rail network had reached 48,000 kilometers in operating length—over 70% of the world’s total. With the largest high-speed railway system in the world, China has become a global leader in high-speed rail technology. Its bullet trains are now widely recognized as a signature of Chinese innovation and infrastructure.

The event was organized by Contemporary World magazine. The video was Co-presented by China Story Database & CPC Works.